skip to navigation skip to content
Search

pharmaceuticals

Cambridge Network: Study examines cultural fit in big pharma integration

Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. “As I progressed through my EMBA programme in 2018-2019, the BMS acquisition of Celgene was announced…

Read more

Big pharma

Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. Piyush Durani The well-known business expression "culture eats strategy for breakfast" is particularly apt for mergers…

Read more

Cartoon of two business people discussing a pharmaceutical capsule.

Pharma shift

The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…

Read more

2020 webinars whats next 883x432 1

Investing in Cambridge drug discovery

PharmEnable raises £1.8 million for drug discovery expansion. PharmEnable, a venture supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, said it has secured £1.8 million in a seed financing round led by Cambridge…

Read more

2020 news accelerate pharmenable 883x432 1

Biotech vs big pharma

Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…

Read more

2020 brainfood oraiopoulos derisking drug innovation 1998x642 1

Manhattan Project?

A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…

Read more

2020 brainfood manhattan project 883x432 1

Drug trials

An Executive MBA alumnus, Dr Rav Seeruthun, heads a Roche team that has developed a drug being tested to fight COVID-19.  Dr Rav Seeruthun (EMBA 2013) of Cambridge Judge Business School, is heading a team at the Roche UK Medical Directorate that has developed…

Read more

2020 news drug trials 883x432 1

Growth recognition

Cambridge Healthcare Research, co-founded by Cambridge MBA alumnus Max Rubin (MBA 2010), awarded Queen's Award for Enterprise. Cambridge Healthcare Research Ltd, a firm whose Founding Partner is Cambridge MBA graduate Max Rubin (MBA 2010), was awarded a Queen's Award for…

Read more

2020 news growth recognition 883x432 2

Cambridge Executive MBA participants respond to the COVID-19 crisis

Participants in the 2019 cohort the Cambridge Executive MBA programme have implemented rapid changes within their respective organisations to respond to issues related to the COVID-19 (coronavirus) crisis. By considering how they can adapt organisational assets, utilise professional competencies and…

Read more

2020 emba emba participants respond to covid 19 crisis 883x432 1

Fast Company: How open-source medicine could prepare us for the next pandemic

A study on drug repurposing co-authored by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. The study found that “about 31 per cent of drugs approved by the FDA had…

Read more

Archives